Literature DB >> 20224984

Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Hiromichi Ito1, Michael Abramson, Kaori Ito, Edward Swanson, Nancy Cho, Daniel T Ruan, Richard S Swanson, Edward E Whang.   

Abstract

BACKGROUND: The aims of this study were to evaluate contemporary outcomes associated with the surgical management of pancreatic neuroendocrine tumors (PNETs) and to assess the prognostic value of the World Health Organization (WHO) classification and TNM staging for PNETs.
METHODS: The medical records of 73 consecutive patients with PNETs treated at a single institution from January 1992 through September 2006 were reviewed. Survival was analyzed with the Kaplan-Meier method (median follow-up: 43 months).
RESULTS: Median patient age was 52 years (range, 19-83 years), and 36 (49%) patients were male. Thirty-three patients had a well-differentiated neuroendocrine tumor (WDT), 26 had a well-differentiated neuroendocrine carcinoma (WDCa), and 14 had a poorly differentiated neuroendocrine carcinoma (PDCa). Fifty (68%) patients underwent potentially curative resection, and the 5-year disease-specific survival (DSS) rate for the entire cohort was 62%. WHO classification and TNM staging system provided good prognostic stratification of patients; 5-year DSS rates were 100% for WDT, 57% for WDCa, 8% for PDCa, respectively, by WHO classification (p < 0.001), and 100% for stage 1, 90% for stage 2, 57% for stage 3, and 8% for stage 4, respectively, by TNM stage (p < 0.001). Among the patients who underwent potentially curative resection, nodal status, distant metastasis, and tumor grade were significant prognostic factors.
CONCLUSION: WHO classification and TNM staging are useful for prognostic stratification among patients with PNETs.

Entities:  

Mesh:

Year:  2010        PMID: 20224984     DOI: 10.1007/s11605-010-1173-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

2.  Endocrine pancreatic tumors: factors correlated with survival.

Authors:  P Tomassetti; D Campana; L Piscitelli; R Casadei; D Santini; F Nori; A M Morselli-Labate; R Pezzilli; R Corinaldesi
Journal:  Ann Oncol       Date:  2005-08-05       Impact factor: 32.976

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients.

Authors:  G Q Phan; C J Yeo; J L Cameron; M M Maher; R H Hruban; R Udelsman
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

5.  Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry.

Authors:  Timothy L Fitzgerald; Zach J Hickner; Matthew Schmitz; Eric J Kort
Journal:  Pancreas       Date:  2008-08       Impact factor: 3.327

6.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Authors:  Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

Review 7.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

8.  Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.

Authors:  Karl Y Bilimoria; David J Bentrem; Ryan P Merkow; James S Tomlinson; Andrew K Stewart; Clifford Y Ko; Mark S Talamonti
Journal:  J Am Coll Surg       Date:  2007-08-03       Impact factor: 6.113

9.  Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.

Authors:  L Fischer; J Kleeff; I Esposito; U Hinz; A Zimmermann; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  20 in total

1.  Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Claudio Pasquali; Guido Rindi; Gianfranco Delle Fave; Marco Del Chiaro; Riccardo Casadei; Massimo Falconi
Journal:  Langenbecks Arch Surg       Date:  2010-09-21       Impact factor: 3.445

2.  Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?

Authors:  Ding Ding; Ammar A Javed; Chunhui Yuan; Michael J Wright; Zunaira N Javed; Jonathan A Teinor; I Chae Ye; Richard A Burkhart; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Gastrointest Surg       Date:  2020-02-05       Impact factor: 3.452

3.  Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection.

Authors:  Thomas Curran; Barbara A Pockaj; Richard J Gray; Thorvardur R Halfdanarson; Nabil Wasif
Journal:  J Gastrointest Surg       Date:  2014-08-14       Impact factor: 3.452

4.  Outcomes of 101 Consecutive Surgical Resections of Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs) at Tata Memorial Hospital: a Referral Bias for Nonfunctional Duodenopancreatic Tumours and the Need for Greater Awareness of GEPNETs as a Distinct Entity.

Authors:  Vinay Gaikwad; Shraddha Patkar; Savio George Barreto; Bhawna Sirohi; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg       Date:  2016-02-13       Impact factor: 0.656

Review 5.  Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection.

Authors:  Paige Finkelstein; Rishika Sharma; Omar Picado; Rahul Gadde; Heather Stuart; Caroline Ripat; Alan S Livingstone; Danny Sleeman; Nipun Merchant; Danny Yakoub
Journal:  J Gastrointest Surg       Date:  2017-03-02       Impact factor: 3.452

6.  One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques.

Authors:  Joseph DiNorcia; Minna K Lee; Patrick L Reavey; Jeanine M Genkinger; James A Lee; Beth A Schrope; John A Chabot; John D Allendorf
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

7.  Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas.

Authors:  De-shen Wang; Dong-sheng Zhang; Miao-zhen Qiu; Zhi-qiang Wang; Hui-yan Luo; Feng-hua Wang; Yu-hong Li; Rui-hua Xu
Journal:  Tumour Biol       Date:  2011-04-09

8.  Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas.

Authors:  Claudius Conrad; Onur C Kutlu; Arvind Dasari; Jennifer A Chan; Jean-Nicolas Vauthey; David B Adams; Michael Kim; Jason B Fleming; Matthew H G Katz; Jeffrey E Lee
Journal:  J Gastrointest Surg       Date:  2016-10-06       Impact factor: 3.452

9.  Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Xavier M Keutgen; Naris Nilubol; Joanne Glanville; Samira M Sadowski; David J Liewehr; David J Venzon; Seth M Steinberg; Electron Kebebew
Journal:  Surgery       Date:  2015-10-06       Impact factor: 3.982

10.  Nomogram for predicting survival of patients with metastatic nonfunctioning pancreatic neuroendocrine tumors: A SEER based study.

Authors:  Lina Ge; Haijin Li; Liang Dong; Guanmin Shang; Weiying Wang; Ying Li; Liping Qi; Jiangang Zhao; Dengfu Peng; Guoqi Tong
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.